ResMed (RMD)
(Delayed Data from NYSE)
$226.64 USD
+3.23 (1.45%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $226.64 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
RMD 226.64 +3.23(1.45%)
Will RMD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RMD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RMD
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
RMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
What's in Store for Cardinal Health (CAH) in Q4 Earnings?
ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy?
ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy?
Other News for RMD
Baird Q2 2024 Mid Cap Growth Equity Fund Commentary
ResMed Inc Updates Dividend Exchange Rate
ResMed Inc. Welcomes New Board Member
ResMed Welcomes Christopher DelOrefice to Board of Directors
ResMed Expands its Board of Directors and Appoints Healthcare Executive and Seasoned Finance Leader Christopher DelOrefice to its Board